Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
Desoxycorticosterone acetate (DOCA) is a synthetic mineralocorticoid steroid administered by injection, approved in 1939. It acts as a corticosteroid replacement therapy for adrenocortical insufficiency and related endocrine disorders. DOCA is a legacy product with decades of clinical use in niche indications requiring mineralocorticoid support.
Approaching loss of exclusivity with minimal commercial infrastructure; limited headcount and legacy support model typical of geriatric injectables.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Localized Injection of Lidocaine Via the Middle Meningeal Artery for Headache Treatment
Study to Assess Adverse Events and How Effective NOA LIFT is Compared to JUVÉDERM VOLIFT With Lidocaine for the Correction of Nasolabial Folds in Adults
Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
Percutaneous AngioVac Vegetation Extraction (PAVE) to Remove Right Heart Vegetations in Patients With Infective Endocarditis
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Worked on DOCA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
DOCA offers minimal career growth opportunity; 0 linked job openings reflects negligible hiring activity. Positions on this product are typically maintenance-focused roles with limited visibility and advancement potential within modern pharma career paths.